B+
Bull case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
CADL
Candel TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Candel has a positive phase 3 prostate-cancer dataset, a planned Q4 2026 BLA, an activated AURORA phase 3 program in NSCLC, and stated runway into Q1 2028 [#SEC-8K-2026-08-13]. Successful regulatory progress could support a substantial re-rating.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.3.
What can break
A reported open-market sale by the chief scientific officer adds a modest insider-sentiment caution [#SEC-FORM4-2026-07-01].
Momentum
95
Value
41
Sentiment
86
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.50 · Bull $20.00 · Bear $8.50Analysis 2026-09-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $21.00
Why
Momentum95 · Δ7d +0.7
Value41 · Δ7d 0.0
Sentiment86 · Δ7d -5.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -5.3.
Contradictions & invalidation
- • A reported open-market sale by the chief scientific officer adds a modest insider-sentiment caution [#SEC-FORM4-2026-07-01].
- • AURORA NSCLC and linoserpaturev programs remain exposed to clinical-development and readout risk.
- • The thesis remains binary around regulatory execution, manufacturing, commercialization, and future clinical development.
Catalyst clock
2026-09-30
ASTRO biomarker data may strengthen the prostate-cancer filing case
Lead driver: Sentiment · See AI snapshot
Momentum
95
9% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+0.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
86
62% active weight
Current posture
7d trendSoftening
Δ7d
-5.3
Δ21d
+53.5
Why this grade
Composite grade A. Momentum 95.4 / Value 41.2 / Sentiment 85.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-07. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$930.47M
Beta
-0.93
Shares Out
76.52M
P/E (TTM) · Derived
-16.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-13.19
Rev YoY
-100.0%
EPS YoY
+463.7%
Gross Margin
-3654.8%
Op Margin
-
Net Debt
-$70.7M
Current Ratio
16.09
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data